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A 20-year-old man presented with a non-healing ulcer
on the dorsum of the left foot that initially appeared
after the patient fell and hit his left foot on the edge
of a door. An ulcer had formed and grown in size over
the past several weeks after repeated physical insults
and despite home wound care, as seen in Figure 1.
Additionally, the patient had a non-healing ulcer inferior
to his left knee. He had a notable past medical history
of acute myelogenous leukemia (AML) in remission
after a haploidentical stem cell transplant, uncontrolled
diabetes type 1, and graft-versus-host disease of the
skin. Both wounds showed no signs of osteomyelitis or
cellulitis on MRI.
The patient’s ulcers most closely resembled pyoderma
gangrenosum (PG), and his history was consistent with
the pathergy associated with this disease. Pathergy is
defined as the evidence of new skin lesions arising at
sites of intradermal trauma due to an inflammatory
response mediated largely by neutrophils. 1 Pathergy
is also seen in bowel associated dermatosis-arthritis
syndrome, Behcet’s disease, and rheumatoid arthritis.
PG occurs most frequently in the lower extremities
and can be divided into five subgroups: classic,
bullous, pustular, vegetative, and peristomal types.2
Lesions usually start as tender nodules, plaques, or
sterile pustules that become larger with trauma and
debridement. Over several days to a week, the lesion
often enlarges into a sharply demarcated ulcer with
violaceous borders and a zone of erythema. PG lesions
are extremely painful. They are thought to arise from
loss of innate immune regulation and altered neutrophil
chemotaxis.2 AML is the most common hematologic
malignancy that underlies PG, with the bullous subtype
of PG being the predominant type found in these cases.
PG lesion development foreshadows a poor prognosis
in AML, and its presence in myelodysplastic syndromes
may herald a malignant transformation.1 Chronic and
atypical cases have a higher association with underlying
AML and myelodysplastic syndromes than typical cases.

Figure 1: Pyoderma gangrenosum of left foot

PG is treated with anti-inflammatory agents such as
steroids and tumor necrosis factor-alpha inhibitors. If PG
appears as a dermatologic manifestation of a systemic
disease, treating the systemic disease is necessary.3
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